Provided by Tiger Trade Technology Pte. Ltd.

Enliven Treateutics

46.97
+0.76001.64%
Post-market: 46.970.00000.00%19:30 EDT
Volume:1.12M
Turnover:52.60M
Market Cap:3.44B
PE:-28.04
High:47.43
Open:47.38
Low:45.92
Close:46.21
52wk High:62.32
52wk Low:14.79
Shares:73.27M
Float Shares:61.73M
Volume Ratio:1.07
T/O Rate:1.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6753
EPS(LYR):-1.8300
ROE:-15.31%
ROA:-11.00%
PB:3.84
PE(LYR):-25.67

Loading ...

Enliven initiated with an Overweight at Morgan Stanley

TIPRANKS
·
Oct 02

Enliven Therapeutics, Inc. : JP Morgan Initiates Coverage with Overweight Rating; Target Price $75

THOMSON REUTERS
·
Oct 01

Enliven Therapeutics CMO Helen Louise Collins Disposes of USD 250,000 in Common Shares

Reuters
·
Sep 22

Enliven Therapeutics Management to Attend Morgan Stanley Global Healthcare Conference Fireside Chat

Reuters
·
Sep 04

Enliven Therapeutics to Present Phase 1 Enable Trial Data for ELVN-001 in CP-CML at SOHO 2026

Reuters
·
Sep 01

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (Soho) 2026 Annual Meeting

THOMSON REUTERS
·
Sep 01

Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX)

TIPRANKS
·
Aug 24

Enliven Therapeutics CMO Helen Louise Collins Reports Disposal of 5,000 Common Shares Worth $293,612.17

Reuters
·
Aug 20

Enliven Therapeutics, Inc. : Mizuho Raises Target Price to $73 from $62

THOMSON REUTERS
·
Aug 18

Enliven initiated with an Outperform at William Blair

TIPRANKS
·
Aug 18

Enliven Therapeutics, Inc. : William Blair Initiates Coverage with Outperform Rating

THOMSON REUTERS
·
Aug 18

U.S. Research Roundup- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies

Reuters
·
Aug 17

Enliven Therapeutics (ELVN) Gets a Buy from Stifel Nicolaus

TIPRANKS
·
Aug 13

Enliven Therapeutics Director Mika K. Derynck Sells USD 9.56 Million in Common Shares

Reuters
·
Aug 07

Stifel Nicolaus Reaffirms Their Buy Rating on Enliven Therapeutics (ELVN)

TIPRANKS
·
Aug 06

Climb Bio Q2 Net Loss Widens on Pipeline Advancement

Reuters
·
Aug 06

Aclaris Therapeutics Q2 Revenue Beats Analyst Estimates

Reuters
·
Aug 06

Enliven Therapeutics, Inc. : Jefferies Raises Target Price to $69 from $59

THOMSON REUTERS
·
Aug 06

Enliven Therapeutics, Inc. : Guggenheim Cuts Target Price to $78 from $80

THOMSON REUTERS
·
Aug 06

Enliven Therapeutics Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 06